| Date | Title | Description |
| 21.07.2026 | Colossal Biosciences punta a 30 miliardi | Colossal Biosciences sarebbe in trattativa per raccogliere nuovi capitali a una valutazione compresa tra 20 e 30 miliardi di dollari. A riportarlo è Axios, che non ha indicato né il potenziale lead investor né l’ammontare complessivo del ro... |
| 01.07.2026 | Colossal Foundation and University of Tasmania Partner to Combat Devil Facial Tumour Disease with Vaccines and Gene Editing | The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines across Tasmania
DALLAS and HOBART, Australia... |
| 29.09.2025 | Future-Proofing Biodiversity: Colossal's Strategy to Preserve What Can't Be Replaced | Created by Carl Williams
Published: Sep 29 2025, 22:52 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 01.07.2025 | The Future of Conservation: Merging Technology and Nature | In the heart of the conservation debate lies a paradox. Traditional funding for conservation often feels like a drop in the ocean. Resources are scarce, and choices are painful. Enter Colossal, a company reshaping the landscape of conservat... |
| 29.06.2025 | Conservation Economics: How De-Extinction Technology Creates New Funding Models | The dire wolf breakthrough represents more than a scientific achievement—it demonstrates how innovative funding models can support conservation without competing with traditional resources.
Colossal’s approach has attracted over $200 millio... |
| 20.06.2025 | What Colossal's Dire Wolves Mean for Biodiversity Protection | Created by Carl Williams
Published: Jun 20 2025, 23:21 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 16.01.2025 | The Dawn of De-Extinction: Colossal Biosciences Rises to New Heights | In a world where extinction looms like a dark cloud, a beacon of hope has emerged. Colossal Biosciences, a Dallas-based startup, is rewriting the rules of biology. With a recent $200 million Series C funding round, the company has soared to... |
| 16.01.2025 | Colossal: $200 Million (Series C) Raised At $10.2 Billion Valuation For De-Extinction Technology | De-extinction company Colossal Biosciences announced $200 million in a Series C funding round by TWG Global, jointly led by Mark Walter and Thomas Tull. And Colossal’s additional strategic investors include funds such as USIT, Animal Capita... |
| 15.01.2025 | Colossal Secures $200M in Series C Funding From TWG Global on the Back of Numerous World’s First Scientific Breakthroughs on Path to De-Extinction | Funding allows for expansion of labs, teams, and additional species candidates for de-extinction
DALLAS–(BUSINESS WIRE)–January 15, 2025–
Colossal Biosciences, the world’s first de-extinction company, has today announced $200M in a Series C... |
| - | The Colossal Foundation | “We started The Colossal Foundation to ensure that our technology can be in the hands of those who can benefit the most. The Foundation further expands our capacity to get our science into the world as fast as possible; in the face of this ... |
